Sab Biotherapeutics, INC 10-Q quarterly reports

SAB Biotherapeutics, Inc. reported a net loss of $22.5 million for the second quarter of 2026, with operating expenses nearly tripling year-over-year, driven by increased clinical trial costs for its lead candidate SAB-142.

SAB Biotherapeutics details significant R&D investment and progress in its lead Type 1 Diabetes therapy, SAB-142, alongside a substantial capital raise.

SAB Biotherapeutics reported a significant financial turnaround in Q3 2025, driven by a $175 million capital raise and reclassification of warrants, while advancing its lead T1D candidate, SAB-142, into Phase 2b.

SAB Biotherapeutics reported increased net losses and no revenue for Q2 2025, but secured $175 million in gross proceeds from a Series B private placement to fund its lead T1D candidate's Phase 2b study.

SAB Biotherapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash and investments.

SAB Biotherapeutics reported its Q3 2024 financial results, highlighting progress in its SAB-142 clinical trial for Type 1 Diabetes and ongoing financial challenges.

SAB Biotherapeutics reported its second quarter 2024 financial results, highlighting progress in its SAB-142 Type 1 Diabetes program and a strategic rebrand to SAB BIO.

SAB Biotherapeutics reported a net loss of $5.0 million for the first quarter of 2024, alongside increased research and development expenses and progress in its SAB-142 clinical trial.